{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"All adverse events (AEs) which occurred after signed informed consent were documented in the source records and on the respective AE Case Report Form (CRF). Toxicity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Scale (Version 3.0).","groups":[{"description":"Three doses of ipilimumab, 3 mg/kg, were administered by intravenous infusion at 3-week intervals. A 6-week observation period followed the final dose.","id":"OG000","title":"Ipilimumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All subjects who entered the study.","reportingStatus":"POSTED","timeFrame":"up to 13 weeks","title":"Number of Subjects Reporting Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}